EpiCongress London is a premier networking, interactive and solution-led conference that addresses how to understand the basic mechanisms behind genome regulation and chromatin function.
This is a meeting where attendees discover industry-defining information, and expand their network to achieve to ensure effective application of epigenetic science to ensure the success of current and future drug candidates.
Epigenetics is a field growing in importance when it comes to understanding a cell’s transformation to cancer so understanding the epigenetic mechanisms involved will have a significant impact on cancer prevention, diagnosis and therapy.
EpiCongress London will ensure you develop a cutting edge understanding for making clinically relevant predictions and tap into the potential of epigenetics to generate new cancer drugs:
Andrea Cochran Senior Scientist Genentech
Bob CopelandExecutive VP & CSO Epizyme
Peter Staller Director of Oncology Research EpiTherapeutics
Dominique Verhelle Director of Epigenetics Pfizer
"Outstanding... Excellent presentations, variety, very good organisation, great networking sessions. Thanks for preparing and please repeat next year!" GSK
"The speaker array and order was perfect and allowed me to take the maximal amount of knowledge back to the lab" Novartis
"The first conference where I really got a feel for competition in the field. I enjoyed speed networking!" Eli Lilly
"Excellent understanding of the latest developments and competitor landscape in epigenetic drug discovery" Astex Pharmaceuticals